Cancer vaccine cuts melanoma death risk by 42 per cent

Merck and Moderna have released results of a late-stage trial that showed an experimental mRNA vaccine slashed the risk that melanoma returns by 42 per cent.

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.perthnow.com.au)